Progress of Clinical Studies on the Use of Sodium Valproate in Adult Patients with Epilepsy Combined with Nonalcoholic Fatty Liver Disease

VernacularTitle:丙戊酸钠治疗成人癫痫合并非酒精性脂肪性肝病的临床研究进展
Author: Zheng YIN ¹ ; Pei LI ; Kejing LI ; Aiyuan WANG ; Qianqian JI
Author Information

1. 青海大学研究生院,西宁 810007
Keywords: Sodium valproate; Epilepsy; Nonalcoholic fatty liver disease
From: Herald of Medicine 2024;43(9):1429-1434
CountryChina
Language:Chinese
Abstract: Epilepsy patients are prone to obesity and metabolic syndrome(MetS),which is a higher risk than the general population.Nonalcoholic fatty liver disease(NAFLD)is a manifestation of a metabolic syndrome,characterized by hepatic steatosis,which can be exacerbated to some extent in patients with epilepsy.Sodium valproate(VPA),a commonly used clinical antiepileptic drug,leads to triglyceride accumulation in liver cells and induces a risk of NAFLD.In adults with epilepsy combined with NAFLD,treatment with VPA can make the liver,which is already affected by steatosis,more sensitive to VPA-induced liver injury and affect VPA drug metabolism.Both VPA and NAFLD induce hepatic steatosis,and can exacerbate each other's induced hepatic steatosis synergistically during epilepsy treatment.In this paper,we reviewed the progress of clinical studies on the use of VPA in adult patients with epilepsy combined with NAFLD to provide references for effective treatment and future studies of VPA.